Promising Phase 3 Results for Alzheimer ' s Drug Donanemab Promising Phase 3 Results for Alzheimer ' s Drug Donanemab

In a phase 3 trial, the monoclonal antibody donanemab slowed clinical and functional decline by 35% for patients with early Alzheimer ' s disease. However, the drug was not without safety issues.Medscape Medical News

Source: Medscape Psychiatry Headlines - July 17, 2023 Category: Psychiatry Tags: Psychiatry News Source Type: news